HOTH
Hoth Therapeutics, Inc.1.0500
-0.0400-3.67%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
16.29MP/E (TTM)
-Basic EPS (TTM)
-1.02Dividend Yield
0%Recent Filings
10-Q
8-K
Hoth pipeline update filed
Hoth Therapeutics filed presentation materials on October 17, 2025, outlining its pipeline of clinical-stage biopharma assets targeting unmet needs in oncology, dermatology, neurology, and inflammatory diseases. Key highlights include HT-001, a topical gel in Phase 2a trials for EGFR inhibitor-induced skin toxicity, with positive interim data showing reduced inflammation and no approved competitors; HT-KIT advances toward IND submission in 2026 for mast cell cancers. The company reports 15.4 million shares outstanding and cash sufficient for ongoing programs. Investors should note forward-looking statements carry risks from clinical uncertainties.
8-K
Expands crypto treasury reserves
Hoth Therapeutics expanded its treasury reserve strategy on September 10, 2025, gaining board approval to buy up to $1 million in Bitcoin, Ethereum, or Solana, capped at 20% of cash on hand. This move diversifies holdings amid volatile crypto markets, yet exposes the biotech to sharp price swings and no dividend yields. Risks loom large. Untested strategy.
8-K
CEO contract renewed, patent filed
Hoth Therapeutics locked in CEO Robb Knie with a new employment agreement effective August 22, 2025, bumping his base salary to $550,000 and capping annual bonuses at the same amount, while adding a tiered transaction bonus up to 5.5% of equity value for deals like licensing or change of control. The board also granted him 800,000 fully vesting shares on August 27. Separately, the company filed a PCT patent application for HT-001 on August 20, bolstering its cancer treatment pipeline. This setup incentivizes Knie amid IP advances, yet ties payouts to performance hurdles.
10-Q
Q2 FY2025 results
Hoth Therapeutics posted a Q2 net loss of $2.2 million, up 29% year-over-year from $1.7 million, driven by research and development expenses that climbed to $1.0 million from $0.6 million, fueled by $0.7 million in HT-001 manufacturing and clinical work plus $0.3 million for HT-KIT preclinical efforts. The six-month net loss widened to $5.7 million, or $0.44 per share on 13.0 million diluted shares, versus $3.9 million, or $0.68 per share on 5.6 million shares last year, reflecting a $1.3 million patent acquisition expense in January. Cash swelled to $9.0 million, bolstered by $5.6 million from warrant exercises and $1.5 million from ATM sales, yielding $5.2 million in operating cash burn. No revenue yet, but liquidity covers operations for 12 months. Regulatory hurdles could delay approvals.
ACRS
Aclaris Therapeutics, Inc.
3.21+0.04
EDSA
Edesa Biotech, Inc.
1.49-0.00
HCWB
HCW Biologics Inc.
1.78-0.09
HRTX
Heron Therapeutics, Inc.
1.38-0.02
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
KROS
Keros Therapeutics, Inc.
21.53+0.30
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
THAR
Tharimmune, Inc.
2.41+0.01
VNDA
Vanda Pharmaceuticals Inc.
6.65+0.02
XBIT
XBiotech Inc.
2.45-0.08